SG11202002941WA - Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors - Google Patents
Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitorsInfo
- Publication number
- SG11202002941WA SG11202002941WA SG11202002941WA SG11202002941WA SG11202002941WA SG 11202002941W A SG11202002941W A SG 11202002941WA SG 11202002941W A SG11202002941W A SG 11202002941WA SG 11202002941W A SG11202002941W A SG 11202002941WA SG 11202002941W A SG11202002941W A SG 11202002941WA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazine
- pyridine
- triazine compounds
- shp2 inhibitors
- allosteric shp2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571760P | 2017-10-12 | 2017-10-12 | |
| US201862615353P | 2018-01-09 | 2018-01-09 | |
| US201862678889P | 2018-05-31 | 2018-05-31 | |
| PCT/US2018/055502 WO2019075265A1 (en) | 2017-10-12 | 2018-10-11 | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002941WA true SG11202002941WA (en) | 2020-04-29 |
Family
ID=64049755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002941WA SG11202002941WA (en) | 2017-10-12 | 2018-10-11 | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11702411B2 (en) |
| EP (1) | EP3694848A1 (en) |
| JP (1) | JP2020536881A (en) |
| KR (1) | KR20200070295A (en) |
| CN (1) | CN111212834B (en) |
| AU (1) | AU2018347516A1 (en) |
| BR (1) | BR112020007058A2 (en) |
| CA (1) | CA3078565A1 (en) |
| CO (1) | CO2020003714A2 (en) |
| IL (1) | IL273756A (en) |
| MX (1) | MX2020003579A (en) |
| PH (1) | PH12020550216A1 (en) |
| RU (1) | RU2020115095A (en) |
| SG (1) | SG11202002941WA (en) |
| TW (1) | TW201930292A (en) |
| WO (1) | WO2019075265A1 (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (en) | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| CN109475531B (en) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Heterocyclic inhibitors of PTPN11 |
| EA202092442A3 (en) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS |
| KR102457146B1 (en) | 2016-06-14 | 2022-10-19 | 노파르티스 아게 | Compounds and compositions for inhibiting the activity of SHP2 |
| CR20190063A (en) | 2016-07-12 | 2019-05-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (en) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI820013B (en) | 2017-01-23 | 2023-11-01 | 美商銳新醫藥公司 | Bicyclic compounds as allosteric shp2 inhibitors |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| MA49013A (en) | 2017-03-23 | 2021-05-05 | Jacobio Pharmaceuticals Co Ltd | NEW HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| MX2020001425A (en) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing. |
| BR112020004246A2 (en) | 2017-09-07 | 2020-09-01 | Revolution Medicines, Inc. | shp2 inhibitory compositions and methods for the treatment of cancer |
| US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
| TW201930292A (en) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
| MX2020006273A (en) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors. |
| CN112368272B (en) | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | SHP2 inhibitors and uses thereof |
| CN112166110B (en) | 2018-03-21 | 2023-08-11 | 传达治疗有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
| EP3787627A4 (en) | 2018-05-02 | 2021-12-01 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of ptpn11 |
| SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| MX2021003460A (en) | 2018-09-29 | 2021-06-18 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2. |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN111138412B (en) | 2018-11-06 | 2023-09-15 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound and application thereof |
| KR20210135241A (en) | 2019-02-05 | 2021-11-12 | 스카이호크 테라퓨틱스, 인코포레이티드 | Methods and compositions for controlling splicing |
| KR20210135507A (en) | 2019-02-06 | 2021-11-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | Methods and compositions for controlling splicing |
| CN111647000B (en) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | Pyrazine derivative and application thereof in inhibition of SHP2 |
| KR102698608B1 (en) | 2019-04-02 | 2024-08-27 | 어레이 바이오파마 인크. | protein tyrosine phosphatase inhibitor |
| AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| TWI817018B (en) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | Compounds for the treatment of braf-associated diseases and disorders |
| CN112300160A (en) * | 2019-08-01 | 2021-02-02 | 上海奕拓医药科技有限责任公司 | Spiro aromatic ring compound, preparation and application thereof |
| EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
| CN114127053B (en) * | 2019-09-06 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | Substituted pyrazine compound, preparation method and application thereof |
| EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
| CN112724145A (en) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | Pyrazine derivatives for inhibiting SHP2 activity |
| WO2021143680A1 (en) | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | Heteroaryl derivative, preparation method therefor, and use thereof |
| CN114761394B (en) * | 2020-01-16 | 2024-03-29 | 浙江海正药业股份有限公司 | Pyridine or pyrimidine derivative and preparation method and application thereof |
| KR20220148847A (en) | 2020-02-28 | 2022-11-07 | 노파르티스 아게 | Triple Pharmaceutical Combination Comprising Dabrafenib, ERK Inhibitor, and SHP2 Inhibitor |
| US20230212180A1 (en) * | 2020-06-22 | 2023-07-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Substituted pyrazine compound, pharmaceutical composition comprising same, and use thereof |
| CN115916765A (en) * | 2020-07-10 | 2023-04-04 | 浙江海正药业股份有限公司 | Pyridine or pyrimidine derivative and preparation method and application thereof |
| MX2023004802A (en) | 2020-10-27 | 2023-06-22 | Amgen Inc | Heterocyclic spiro compounds and methods of use. |
| CN116568308A (en) * | 2021-01-29 | 2023-08-08 | 四川科伦博泰生物医药股份有限公司 | Heterocyclic SHP2 inhibitor, preparation method and application thereof |
| EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
| TWI825637B (en) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors |
| EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
| CN117651700A (en) | 2021-04-29 | 2024-03-05 | 安进公司 | 2-aminobenzothiazole compounds and methods of use |
| JP2024516037A (en) | 2021-05-05 | 2024-04-11 | フヤバイオ インターナショナル，エルエルシー | Combination therapy comprising an SHP2 inhibitor and a PD-1 inhibitor |
| KR20240007279A (en) * | 2021-05-13 | 2024-01-16 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | Heterocyclic compounds that inhibit SHP2 activity, methods for producing and uses thereof |
| TW202313041A (en) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor. |
| BR112023025916A2 (en) | 2021-06-09 | 2024-02-27 | Chugai Pharmaceutical Co Ltd | COMBINATION OF A BRAF INHIBITOR AND A MEK INHIBITOR, USE OF A COMBINATION, METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER, PHARMACEUTICAL COMPOSITIONS AND INVENTION |
| BR112023025738A2 (en) | 2021-06-09 | 2024-02-27 | Hoffmann La Roche | COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, USE OF A COMBINATION OF A BRAF INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST, METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER, PHARMACEUTICAL COMPOSITION AND INVENTION |
| TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| MX2024000271A (en) | 2021-07-09 | 2024-01-31 | Kanaph Therapeutics Inc | Shp2 inhibitor and use thereof. |
| JP2024532374A (en) | 2021-09-01 | 2024-09-05 | ノバルティス アーゲー | Pharmaceutical combinations containing TEAD inhibitors and their use for the treatment of cancer - Patents.com |
| EP4426305A1 (en) | 2021-11-04 | 2024-09-11 | F. Hoffmann-La Roche AG | Novel use of quinazolinone compound for the treatment of cancer |
| WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| CN118715215A (en) | 2022-02-16 | 2024-09-27 | 美国安进公司 | Quinazoline compounds as inhibitors of mutant KRAS proteins and uses thereof |
| MX2024010045A (en) | 2022-02-16 | 2024-08-26 | Amgen Inc | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins. |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| WO2024022244A1 (en) * | 2022-07-26 | 2024-02-01 | 首药控股(北京)股份有限公司 | Heterocyclic compound having biological activity |
| EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
| WO2024126660A1 (en) | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| KR20240110741A (en) * | 2023-01-05 | 2024-07-16 | 주식회사 카나프테라퓨틱스 | Shp2 inhibitors and use thereof |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
Family Cites Families (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2572728A (en) | 1949-01-07 | 1951-10-23 | American Cyanamid Co | Hydroxybenzenesulfonamidopyra-zines and preparation of same |
| US2636882A (en) | 1950-08-11 | 1953-04-28 | Quaker Oats Co | Preparation of 3-pyridols from 2-acylfurans |
| BE758503A (en) | 1969-11-07 | 1971-05-05 | Shell Int Research | PESTICIDE COMPOSITIONS |
| GB1459571A (en) | 1974-09-12 | 1976-12-22 | Pfizer Ltd | Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus |
| JPS5762269A (en) | 1980-10-03 | 1982-04-15 | Ogawa Koryo Kk | 2,3,5-trisubstituted pyrazine derivative |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| DE3242195A1 (en) | 1982-11-15 | 1984-05-17 | Basf Ag, 6700 Ludwigshafen | NEW 2-AMINOPYRAZINE AND METHOD FOR PRODUCING 2-AMINOPYRAZINE AND PYRAZINE |
| JPH0249775A (en) | 1988-05-19 | 1990-02-20 | Nippon Soda Co Ltd | Heterocyclic compound having 6-membered or 7-membered ring and production thereof |
| JPH04112877A (en) | 1990-09-04 | 1992-04-14 | Nippon Soda Co Ltd | New cyanopyrazine derivative and production thereof |
| WO1993009664A1 (en) | 1991-11-12 | 1993-05-27 | Nippon Soda Co., Ltd. | Wavelength conversion material for agriculture |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| GB9504854D0 (en) | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| EE04282B1 (en) | 1996-02-07 | 2004-04-15 | Janssen Pharmaceutica N.V. | Pyrazole Pyrimidines, Their Preparation and Use as a Pharmaceutical, and Composition Containing Them |
| JP2002512628A (en) | 1997-06-13 | 2002-04-23 | スージェン・インコーポレーテッド | Novel heteroaryl compounds for regulating protein tyrosine enzyme-related cell signaling |
| AU775625B2 (en) | 1999-08-27 | 2004-08-05 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
| CZ20022739A3 (en) | 2000-02-16 | 2003-02-12 | Neurogen Corporation | Substituted arylpyrazines |
| CA2495529C (en) | 2001-10-01 | 2009-05-19 | Mount Sinai School Of Medicine Of New York University | Noonan syndrome gene |
| US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| AU2002343557A1 (en) | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | Substituted 2,3-diphenyl pyridines |
| US20040116444A1 (en) | 2002-09-12 | 2004-06-17 | Corbett Jeffrey W. | Substituted 1,4-pyrazine derivatives |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| WO2004099201A1 (en) | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Compounds as crf1 receptor antagonists |
| GB0314057D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| FR2856684B1 (en) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | DIPHENYLPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US20050070542A1 (en) | 2003-09-03 | 2005-03-31 | Hodgetts Kevin J. | 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| ES2288270T3 (en) | 2003-10-10 | 2008-01-01 | Pfizer Products Incorporated | 2H- (1,2,4) TRIAZOLO (4,3-A) REPLACED PIRAZINS AS INHIBITORS OF GSK-3. |
| RU2006118325A (en) | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Pyrazine Derivatives and Their Pharmaceutical Use |
| DE102004015954A1 (en) | 2004-04-01 | 2005-11-10 | Ina-Schaeffler Kg | belt drive |
| CA2562126A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| JP2008503591A (en) | 2004-06-22 | 2008-02-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ubiquitin ligase inhibitor |
| WO2006071759A2 (en) | 2004-12-23 | 2006-07-06 | Mallinckrodt Inc. | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| AU2006261993B2 (en) | 2005-06-22 | 2011-11-17 | Plexxikon, Inc. | Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors |
| JP5671206B2 (en) | 2005-10-21 | 2015-02-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Mutation of c-KIT oncogene in melanoma |
| CA2616147A1 (en) | 2006-02-24 | 2007-09-20 | Mallinckrodt Inc. | Process for using optical agents |
| JP2007277097A (en) | 2006-04-03 | 2007-10-25 | Mie Univ | Luminous compound, method for emitting light, and method for producing luminous compound |
| WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
| AU2007243280A1 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| DE602007006010D1 (en) | 2006-05-31 | 2010-06-02 | Galapagos Nv | TRIAZOLOPYRAZIN COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES |
| JP2009539840A (en) | 2006-06-06 | 2009-11-19 | シェーリング コーポレイション | Imidazopyrazine as a protein kinase inhibitor |
| US8313729B2 (en) | 2007-03-01 | 2012-11-20 | Medibeacon, LLC | Integrated photoactive small molecules and uses thereof |
| EP2144909B1 (en) | 2007-04-06 | 2011-03-23 | Novartis AG | [2,6]naphthyridines useful as protein kinase inhibitors |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2008138843A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases |
| JPWO2008156174A1 (en) | 2007-06-21 | 2010-08-26 | 大正製薬株式会社 | Pyrazineamide compound |
| WO2009020642A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| WO2009025823A1 (en) * | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
| AU2009308982A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| WO2010141275A1 (en) * | 2009-06-01 | 2010-12-09 | Merck Sharp & Dohme Corp. | Pyrazine carboxamide orexin receptor antagonists |
| JP2013502424A (en) | 2009-08-17 | 2013-01-24 | メモリアル スローン−ケタリング キャンサー センター | Heat shock protein binding compounds, compositions, and methods for making them |
| WO2011026242A1 (en) | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
| US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| JP5833105B2 (en) * | 2010-05-11 | 2015-12-16 | サノフイ | Substituted N-heteroaryl spirolactam bipyrrolidines, their preparation and therapeutic use |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| CA2804744C (en) | 2010-07-14 | 2019-05-28 | Novartis Ag | Ip receptor agonist 1,8-naphthyridinyl and 7,8-dihydropyrido[3,2-b]pyrazinyl heterocyclic compounds |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2012149280A2 (en) | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
| CN103181918B (en) | 2011-05-04 | 2014-10-29 | 厦门大学 | Application of fatty acid compound in preparation of medicines for preventing and treating liver cancer |
| EP2802583A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| WO2014023385A1 (en) | 2012-08-07 | 2014-02-13 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
| MX2015005812A (en) | 2012-11-08 | 2015-09-23 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands. |
| SG11201504212WA (en) | 2012-11-29 | 2015-06-29 | Chemocentryx Inc | Cxcr7 antagonists |
| WO2014113584A1 (en) | 2013-01-16 | 2014-07-24 | Rhode Island Hospital | Compositions and methods for the prevention and treatment of osteolysis and osteoporosis |
| CA2900303A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 |
| HUE046961T2 (en) | 2013-02-20 | 2020-04-28 | Univ Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
| CN103554038B (en) | 2013-06-19 | 2015-10-14 | 云南大学 | Phenyl polyhalide nitrile quinazolinones and its production and use |
| JO3517B1 (en) * | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| WO2015107494A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| US10093646B2 (en) * | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| WO2015164862A1 (en) | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
| TWI687419B (en) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors |
| KR20170038877A (en) * | 2014-08-01 | 2017-04-07 | 누에볼루션 에이/에스 | Compounds active towards bromodomains |
| US10472347B2 (en) | 2014-11-18 | 2019-11-12 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| ES2881305T3 (en) | 2014-12-17 | 2021-11-29 | Siemens Healthcare Diagnostics Inc | Sandwich Assay Design for Small Molecules |
| CN107108637B (en) | 2014-12-23 | 2019-10-29 | 诺华股份有限公司 | Triazolopyrimidine compound and application thereof |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| ES2808781T3 (en) | 2015-02-05 | 2021-03-01 | Tyrnovo Ltd | Combinations of dual IRS / STAT3 modulators and anticancer agents for the treatment of cancer |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CN107787323B (en) | 2015-06-19 | 2020-09-01 | 诺华股份有限公司 | Compounds and compositions for inhibiting SHP2 activity |
| CN112625028B (en) * | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | Compounds and compositions for inhibiting SHP2 activity |
| WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2017011618A1 (en) | 2015-07-15 | 2017-01-19 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of sirna and drug |
| EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| GB201604970D0 (en) * | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| GB201604969D0 (en) * | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| EA202092442A3 (en) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS |
| KR102457146B1 (en) * | 2016-06-14 | 2022-10-19 | 노파르티스 아게 | Compounds and compositions for inhibiting the activity of SHP2 |
| CR20190063A (en) | 2016-07-12 | 2019-05-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (en) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2 phosphatase inhibitors and methods of use thereof |
| ES2964956T3 (en) * | 2017-01-10 | 2024-04-10 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
| TWI820013B (en) | 2017-01-23 | 2023-11-01 | 美商銳新醫藥公司 | Bicyclic compounds as allosteric shp2 inhibitors |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| MA49013A (en) | 2017-03-23 | 2021-05-05 | Jacobio Pharmaceuticals Co Ltd | NEW HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS |
| EP3606492A4 (en) | 2017-04-05 | 2020-11-11 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| EP3607326A4 (en) | 2017-04-05 | 2020-11-18 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| BR112020004246A2 (en) | 2017-09-07 | 2020-09-01 | Revolution Medicines, Inc. | shp2 inhibitory compositions and methods for the treatment of cancer |
| TW201930292A (en) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
| MX2020006273A (en) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors. |
| CN110156786B (en) | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | Pyrimido-cyclic compounds, process for their preparation and their use |
| KR102614939B1 (en) | 2018-02-13 | 2023-12-19 | 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 | Pyrimidine-fused ring compounds and their production methods and uses |
| CN112368272B (en) * | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | SHP2 inhibitors and uses thereof |
| WO2019199792A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
| US20190336609A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors |
| AU2019262979B2 (en) | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
| AU2019338207A1 (en) | 2018-09-10 | 2021-04-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3113234A1 (en) * | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| EP3863636A1 (en) | 2018-10-08 | 2021-08-18 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
| EP3878853A4 (en) | 2018-11-07 | 2022-12-14 | Shanghai Ringene BioPharma Co., Ltd. | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| MX2021006026A (en) | 2018-11-30 | 2021-07-06 | Tuojie Biotech Shanghai Co Ltd | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof. |
| US20220073521A1 (en) | 2018-11-30 | 2022-03-10 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
| US20200197391A1 (en) | 2018-12-21 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| TW202132315A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
-
2018
- 2018-10-11 TW TW107135797A patent/TW201930292A/en unknown
- 2018-10-11 EP EP18795913.5A patent/EP3694848A1/en active Pending
- 2018-10-11 RU RU2020115095A patent/RU2020115095A/en unknown
- 2018-10-11 KR KR1020207013076A patent/KR20200070295A/en not_active Application Discontinuation
- 2018-10-11 WO PCT/US2018/055502 patent/WO2019075265A1/en active Application Filing
- 2018-10-11 JP JP2020519790A patent/JP2020536881A/en active Pending
- 2018-10-11 BR BR112020007058-0A patent/BR112020007058A2/en not_active Application Discontinuation
- 2018-10-11 MX MX2020003579A patent/MX2020003579A/en unknown
- 2018-10-11 AU AU2018347516A patent/AU2018347516A1/en not_active Abandoned
- 2018-10-11 SG SG11202002941WA patent/SG11202002941WA/en unknown
- 2018-10-11 CA CA3078565A patent/CA3078565A1/en not_active Abandoned
- 2018-10-11 CN CN201880066291.0A patent/CN111212834B/en active Active
-
2020
- 2020-03-27 CO CONC2020/0003714A patent/CO2020003714A2/en unknown
- 2020-03-31 PH PH12020550216A patent/PH12020550216A1/en unknown
- 2020-04-01 IL IL273756A patent/IL273756A/en unknown
- 2020-04-10 US US16/845,539 patent/US11702411B2/en active Active
-
2023
- 2023-04-05 US US18/131,226 patent/US20240067636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020007058A2 (en) | 2020-10-06 |
| CO2020003714A2 (en) | 2020-04-24 |
| MX2020003579A (en) | 2020-07-22 |
| CN111212834B (en) | 2024-01-19 |
| JP2020536881A (en) | 2020-12-17 |
| EP3694848A1 (en) | 2020-08-19 |
| RU2020115095A (en) | 2021-11-12 |
| CN111212834A (en) | 2020-05-29 |
| US20200339552A1 (en) | 2020-10-29 |
| AU2018347516A1 (en) | 2020-05-07 |
| KR20200070295A (en) | 2020-06-17 |
| PH12020550216A1 (en) | 2021-02-15 |
| US20240067636A1 (en) | 2024-02-29 |
| RU2020115095A3 (en) | 2022-01-31 |
| TW201930292A (en) | 2019-08-01 |
| US11702411B2 (en) | 2023-07-18 |
| IL273756A (en) | 2020-05-31 |
| WO2019075265A1 (en) | 2019-04-18 |
| CA3078565A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273756A (en) | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors | |
| IL268031B (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| LT3601239T (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG10202110874TA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| IL282386A (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| IL246362B (en) | Novel glutaminase inhibitors incorporating nitrogen-containing heterocycles | |
| HK1248070A1 (en) | Heterocyclic compounds as kinase inhbitors | |
| IL266745B (en) | Benzodiazolium compounds as enac inhibitors | |
| IL258513B (en) | Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors | |
| ZA201901543B (en) | Heterocyclic compound, and harmful-arthropod-controlling agent containing same | |
| HK1249105A1 (en) | Nitrogen-containing heterocyclic compound | |
| IL259360B (en) | Diamino pyridine derivatives | |
| IL263652A (en) | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors | |
| HK1253913A1 (en) | Triazine derivatives as interferon-gamma inhibitors | |
| EP3347357A4 (en) | Heterocyclic tec-family kinase inhibitors | |
| IL270873A (en) | Pyridine and pyrazine compounds | |
| IL269598A (en) | Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors |